Omeros (OMER) Cash from Operations (2010 - 2026)
Omeros recorded quarterly Cash from Operations of 14506000.0 in Q1 2026, up 63.59% quarter-over-quarter from 39842000.0 in Q4 2025, and up 59.53% year-over-year from 9093143.03 in Q1 2025.
Omeros' Cash from Operations history runs 17 years deep, the most recent figure standing at 14506000.0 for Q1 2026.
- In Q1 2026, Cash from Operations rose 59.53% year-over-year to 14506000.0; the TTM figure through Mar 2026 stood at 94759000.0 (up 33.67% YoY), while the FY2025 annual figure was 116094000.0, up 21.98% from the prior year.
- Cash from Operations came in at 14506000.0 for Q1 2026 at Omeros, up from 39842000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 174539000.0 in Q1 2023 to a low of 45985000.0 in Q2 2024.
- A 5-year average of 17127058.82 and a median of 28980000.0 in 2024 frame the typical range for Cash from Operations.
- Across the five-year window, Cash from Operations surged 1248.81% in 2023 and slumped 123.94% in 2024, its largest moves.
- Omeros' Cash from Operations stood at 25382000.0 in 2022, then plunged by 37.2% to 34825000.0 in 2023, then advanced by 16.78% to 28980000.0 in 2024, then tumbled by 37.48% to 39842000.0 in 2025, then jumped by 63.59% to 14506000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 14506000.0, 39842000.0, and 18452000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.43 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.08 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.50 Mn |
| 10 | Omeros | 772.03 Mn | 636.71 Mn | 9.31 Mn | -14.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.51 Mn |
| Mar 31, 2026 | -14.51 Mn |
| Dec 31, 2025 | -39.84 Mn |
| Dec 31, 2025 | -39.84 Mn |
| Sep 30, 2025 | -18.45 Mn |
| Sep 30, 2025 | -18.45 Mn |
| Jun 30, 2025 | -21.96 Mn |
| Jun 30, 2025 | -21.96 Mn |
| Mar 31, 2025 | -35.84 Mn |
| Mar 31, 2025 | -35.84 Mn |
| Dec 31, 2024 | -28.98 Mn |
| Dec 31, 2024 | -28.98 Mn |
| Sep 30, 2024 | -32.06 Mn |
| Sep 30, 2024 | -32.06 Mn |
| Jun 30, 2024 | -45.99 Mn |
| Jun 30, 2024 | -45.99 Mn |
| Mar 31, 2024 | -41.78 Mn |
| Mar 31, 2024 | -41.78 Mn |
| Dec 31, 2023 | -34.83 Mn |
| Dec 31, 2023 | -34.83 Mn |
| Sep 30, 2023 | -32.65 Mn |
| Sep 30, 2023 | -32.65 Mn |
| Jun 30, 2023 | -32.34 Mn |
| Jun 30, 2023 | -32.34 Mn |
| Mar 31, 2023 | 174.54 Mn |
| Mar 31, 2023 | 174.54 Mn |
| Dec 31, 2022 | -25.38 Mn |
| Dec 31, 2022 | -25.38 Mn |
| Sep 30, 2022 | -26.44 Mn |
| Sep 30, 2022 | -26.44 Mn |
| Jun 30, 2022 | -19.47 Mn |
| Jun 30, 2022 | -19.47 Mn |
| Mar 31, 2022 | -15.19 Mn |
| Mar 31, 2022 | -15.19 Mn |
| Dec 31, 2021 | -18.22 Mn |
| Dec 31, 2021 | -18.22 Mn |
| Sep 30, 2021 | -23.66 Mn |
| Sep 30, 2021 | -23.66 Mn |
| Jun 30, 2021 | -27.59 Mn |
| Jun 30, 2021 | -27.59 Mn |
| Mar 31, 2021 | -40.25 Mn |
| Mar 31, 2021 | -40.25 Mn |
| Dec 31, 2020 | -18.41 Mn |
| Dec 31, 2020 | -18.41 Mn |
| Sep 30, 2020 | -34.94 Mn |
| Sep 30, 2020 | -34.94 Mn |
| Jun 30, 2020 | -37.60 Mn |
| Jun 30, 2020 | -37.60 Mn |
| Mar 31, 2020 | -9.14 Mn |
| Mar 31, 2020 | -9.14 Mn |
| Dec 31, 2019 | -23.01 Mn |
| Dec 31, 2019 | -23.01 Mn |
| Sep 30, 2019 | -7.52 Mn |
| Sep 30, 2019 | -7.52 Mn |
| Jun 30, 2019 | -16.59 Mn |
| Jun 30, 2019 | -16.59 Mn |
| Mar 31, 2019 | -12.95 Mn |
| Mar 31, 2019 | -12.95 Mn |
| Dec 31, 2018 | -24.66 Mn |
| Dec 31, 2018 | -24.66 Mn |
| Sep 30, 2018 | -36.87 Mn |
| Sep 30, 2018 | -36.87 Mn |
| Jun 30, 2018 | -30.91 Mn |
| Jun 30, 2018 | -30.91 Mn |
| Mar 31, 2018 | -11.30 Mn |
| Mar 31, 2018 | -11.30 Mn |
| Dec 31, 2017 | -4.17 Mn |
| Dec 31, 2017 | -4.17 Mn |
| Sep 30, 2017 | -11.19 Mn |
| Sep 30, 2017 | -11.19 Mn |
| Jun 30, 2017 | -8.16 Mn |
| Jun 30, 2017 | -8.16 Mn |
| Mar 31, 2017 | -12.70 Mn |
| Mar 31, 2017 | -12.70 Mn |
| Dec 31, 2016 | -10.86 Mn |
| Dec 31, 2016 | -10.86 Mn |
| Sep 30, 2016 | -11.22 Mn |
| Sep 30, 2016 | -11.22 Mn |
| Jun 30, 2016 | -12.80 Mn |
| Jun 30, 2016 | -12.80 Mn |
| Mar 31, 2016 | -16.63 Mn |
| Mar 31, 2016 | -16.63 Mn |
| Dec 31, 2015 | -16.60 Mn |
| Dec 31, 2015 | -16.60 Mn |
| Sep 30, 2015 | -14.59 Mn |
| Sep 30, 2015 | -14.59 Mn |
| Jun 30, 2015 | -16.55 Mn |
| Jun 30, 2015 | -16.55 Mn |
| Mar 31, 2015 | -17.48 Mn |
| Mar 31, 2015 | -17.48 Mn |
| Dec 31, 2014 | -15.69 Mn |
| Dec 31, 2014 | -15.69 Mn |
| Sep 30, 2014 | -15.94 Mn |
| Sep 30, 2014 | -15.94 Mn |
| Jun 30, 2014 | -15.27 Mn |
| Jun 30, 2014 | -15.27 Mn |
| Mar 31, 2014 | -11.14 Mn |
| Mar 31, 2014 | -11.14 Mn |
| Dec 31, 2013 | -296,000.00 |
| Dec 31, 2013 | -296,000.00 |
| Sep 30, 2013 | -11.04 Mn |
| Sep 30, 2013 | -11.04 Mn |
| Jun 30, 2013 | -9.39 Mn |
| Jun 30, 2013 | -9.39 Mn |
| Mar 31, 2013 | -8.97 Mn |
| Mar 31, 2013 | -8.97 Mn |
| Dec 31, 2012 | -12.78 Mn |
| Dec 31, 2012 | -12.78 Mn |
| Sep 30, 2012 | -7.40 Mn |
| Sep 30, 2012 | -7.40 Mn |
| Jun 30, 2012 | -8.86 Mn |
| Jun 30, 2012 | -8.86 Mn |
| Mar 31, 2012 | -5.51 Mn |
| Mar 31, 2012 | -5.51 Mn |
| Dec 31, 2011 | -7.36 Mn |
| Dec 31, 2011 | -7.36 Mn |
| Sep 30, 2011 | -4.11 Mn |
| Sep 30, 2011 | -4.11 Mn |
| Jun 30, 2011 | -6.33 Mn |
| Jun 30, 2011 | -6.33 Mn |
| Mar 31, 2011 | -7.88 Mn |
| Mar 31, 2011 | -7.88 Mn |
| Dec 31, 2010 | 6.62 Mn |
| Dec 31, 2010 | 6.62 Mn |
| Sep 30, 2010 | -5.90 Mn |
| Sep 30, 2010 | -5.90 Mn |